Evidence map›Paper›PMID 40887555›Full record

ReviewWorld journal of urology2025

Dermatological impacts of urological cancer treatments.

Alejandra Sataray-Rodriguez, Damilola Oladinni, Robert Adler, Natasha Doshi, Bailey Patrick, Nicole Aust, Michael Sun, Nina Schur, Scott Jamieson, Jeffrey P Weiss

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alejandra Sataray-RodriguezUniversity of Nevada-Reno School of Medicine, 1664 N Virginia St Reno, Reno, NV, 89512, USA. asatarayrodriguez@med.unr.edu.ORCID http://orcid.org/0000-0002-0194-0606
Damilola OladinniA.T. Still University School of Osteopathic Medicine Arizona, Mesa, AZ, 85206, USA.
Robert AdlerSUNY Downstate Health Sciences University, Brooklyn, NY, USA.ORCID http://orcid.org/0009-0006-7323-9516
Natasha DoshiLake Erie College of Osteopathic Medicine, Bradenton, FL, 34212, USA.
Bailey PatrickUniversity of Missouri School of Medicine, Columbia, MO, USA.
Nicole AustNova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Tampa, FL, USA.
Michael SunSUNY Upstate Medical University, Syracuse, NY, USA.
Nina SchurLake Erie College of Osteopathic Medicine, Bradenton, FL, 34212, USA.
Scott JamiesonSUNY Downstate Health Sciences University, Brooklyn, NY, USA.ORCID http://orcid.org/0000-0002-4553-3041
Jeffrey P WeissSUNY Downstate Health Sciences University, Brooklyn, NY, USA.ORCID http://orcid.org/0000-0001-9564-2724

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urological cancers-including prostate, bladder, renal, and testicular cancers-are commonly treated with surgery, chemotherapy, radiation therapy, and immunotherapy. While these therapies improve survival outcomes, they often induce significant dermatological side effects that impair patients' quality of life and treatment adherence. This review synthesizes current literature on the prevalence, mechanisms, and psychosocial consequences of dermatological toxicities associated with urological cancer treatments. Common adverse effects include dermatitis, alopecia, photosensitivity, hyperpigmentation, and scarring, with severity varying by treatment modality. Chemotherapy frequently causes alopecia and hand-foot syndrome, while radiation therapy leads to dermatitis and long-term fibrosis. Immunotherapy, though revolutionary, is associated with pruritus, vitiligo, and severe cutaneous reactions such as Stevens-Johnson syndrome. The psychosocial burden of these dermatological effects-particularly impacts on body image and self-esteem-is substantial yet understudied. Multidisciplinary management strategies, including early dermatological intervention, patient education, and psychosocial support, are essential to mitigate these effects. Future research should focus on standardized protocols, personalized treatment approaches, and improved patient-reported outcome measures to optimize holistic cancer care.

Indexed as

Skin DiseasesUrologic NeoplasmsAlopeciaAntineoplastic AgentsBody ImageHand-Foot SyndromeHumansImmunotherapyPatient Care TeamPatient CompliancePatient Education as TopicPatient Reported Outcome MeasuresPsychosocial Support SystemsQuality of LifeRadiation InjuriesSelf ConceptAntineoplastic AgentsChemotherapyDermatological toxicityImmunotherapyPsychosocial impactRadiation therapyUrological cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.